Form D · Biotechnology
BioMedomics, Inc.
Research Triangle Park, NC · CIK 0001595601
Offering snapshot reported Jul 28, 2017 · SEC filing
- Reported sold
- $530K Offering amount: $2.73M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 21, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 28, 2017 | Initial | $530,000 | No comparison | 1 | SEC filing |
| Feb 23, 2015 | Initial | $275,752 | No comparison | 6 | SEC filing |
| Jan 6, 2014 | Initial | $690,000 | No comparison | 13 | SEC filing |
| Jan 6, 2014 | Amendment | $690,000 | $0vs Jan 6, 2014 | 13 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-291694
Includes $2,230,000 of new Series B-2 Convertible Preferred Stock and $500,000 Convertible Promissory Note (convertible in shares of B-2 Convertible Preferred Stock).
Source: Form D, filed Jul 28, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Cam Patterson | Director |
| Tom Roberg | Director |
| J. Robert Tyler, Iii | Executive |
| Frank Wang | Director, Executive |
| Phillip S. Wise | Executive |
| Lin Wu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6 Davis Drive
Research Triangle Park, NC, 27709
Research Triangle Park, NC, 27709